{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T10:14:51Z","timestamp":1781345691815,"version":"3.54.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.jcyt.2020.01.015","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T23:05:20Z","timestamp":1586991920000},"page":"214-226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor\u2013T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma"],"prefix":"10.1016","volume":"22","author":[{"given":"Jun-Xia","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Jian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Hua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jcyt.2020.01.015_bib0001","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.6004\/jnccn.2018.0073","article-title":"Chimeric Antigen Receptor T-Cell Therapy","volume":"16","author":"Ogba","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.jcyt.2020.01.015_bib0002","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.jcyt.2020.01.015_bib0003","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1078-0432.CCR-18-2743","article-title":"FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma","volume":"25","author":"Bouchkouj","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.jcyt.2020.01.015_bib0004","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1200\/JCO.18.01457","article-title":"CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma","volume":"37","author":"Jacobson","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2020.01.015_bib0005","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212567","article-title":"Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges","volume":"8","author":"Makita","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.jcyt.2020.01.015_bib0006","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.2147\/CMAR.S163225","article-title":"Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel","volume":"11","author":"Viardot","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"S1","key":"10.1016\/j.jcyt.2020.01.015_bib0007","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/ajh.25445","article-title":"Toxicities of CD19 CAR-T cell immunotherapy","volume":"94","author":"Hirayama","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.jcyt.2020.01.015_bib0008","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10.1016\/j.jcyt.2020.01.015_bib0009","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","article-title":"Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies","volume":"32","author":"Gust","year":"2018","journal-title":"CNS Drugs"},{"issue":"Suppl 1","key":"10.1016\/j.jcyt.2020.01.015_bib0010","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jcyt.2020.01.015_bib0011","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40259-018-0324-z","article-title":"Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities","volume":"33","author":"Dholaria","year":"2019","journal-title":"BioDrugs"},{"issue":"7","key":"10.1016\/j.jcyt.2020.01.015_bib0012","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jcyt.2019.04.005","article-title":"The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies","volume":"21","author":"Cao","year":"2019","journal-title":"Cytotherapy"},{"issue":"16","key":"10.1016\/j.jcyt.2020.01.015_bib0013","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"224","key":"10.1016\/j.jcyt.2020.01.015_bib0014","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"9967","key":"10.1016\/j.jcyt.2020.01.015_bib0015","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.jcyt.2020.01.015_bib0016","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.jcyt.2020.01.015_bib0017","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jcyt.2020.01.015_bib0018","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1027469","article-title":"Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia","volume":"4","author":"Dai","year":"2015","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/j.jcyt.2020.01.015_bib0019","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"13","key":"10.1016\/j.jcyt.2020.01.015_bib0020","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1158\/1078-0432.CCR-16-1799","article-title":"Potent Anti-leukemia Activities of Chimeric Antigen Receptor-Modified T Cells against CD19 in Chinese Patients with Relapsed\/Refractory Acute Lymphocytic Leukemia","volume":"23","author":"Hu","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"355","key":"10.1016\/j.jcyt.2020.01.015_bib0021","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"24","key":"10.1016\/j.jcyt.2020.01.015_bib0022","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","article-title":"Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jcyt.2020.01.015_bib0023","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.jcyt.2020.01.015_bib0024","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/bjh.14923","article-title":"Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation","volume":"179","author":"Chen","year":"2017","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.jcyt.2020.01.015_bib0025","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ymthe.2018.01.022","article-title":"In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia","volume":"26","author":"Cheng","year":"2018","journal-title":"Mol Ther"},{"issue":"7","key":"10.1016\/j.jcyt.2020.01.015_bib0026","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/ajh.25108","article-title":"Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"93","author":"Cao","year":"2018","journal-title":"Am J Hematol"},{"issue":"26","key":"10.1016\/j.jcyt.2020.01.015_bib0027","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jcyt.2020.01.015_bib0028","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jcyt.2020.01.015_bib0029","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jcyt.2020.01.015_bib0030","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00277-018-3246-4","article-title":"CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory\/relapsed acute lymphoblastic leukemia: results of a case-controlled study","volume":"97","author":"Wei","year":"2018","journal-title":"Ann Hematol"},{"issue":"25","key":"10.1016\/j.jcyt.2020.01.015_bib0031","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.jcyt.2020.01.015_bib0032","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jcyt.2020.01.015_bib0033","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jcyt.2020.01.015_bib0034","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/bloodadvances.2019000151","article-title":"Tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion","volume":"3","author":"Bishop","year":"2019","journal-title":"Blood Adv"},{"issue":"52","key":"10.1016\/j.jcyt.2020.01.015_bib0035","doi-asserted-by":"crossref","first-page":"29843","DOI":"10.18632\/oncotarget.25688","article-title":"CD19 directed CAR T cell therapy in diffuse large B-cell lymphoma","volume":"9","author":"Quint\u00e1s-Cardama","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.jcyt.2020.01.015_bib0036","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jcyt.2020.01.015_bib0037","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jcyt.2020.01.015_bib0038","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jcyt.2020.01.015_bib0039","first-page":"276","article-title":"Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma","volume":"40","author":"Xiao","year":"2019","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"4","key":"10.1016\/j.jcyt.2020.01.015_bib0040","first-page":"270","article-title":"Chimeric antigen receptors T cells for treatment of 48 relapsed or refractory acute lymphoblastic leukemia children: long term follow-up outcomes","volume":"40","author":"Zuo","year":"2019","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"6","key":"10.1016\/j.jcyt.2020.01.015_bib0041","first-page":"454","article-title":"Efficacy of anti-CD19 CAR-T cell therapy in 10 refractory recurrent B cell malignancies","volume":"39","author":"Bao","year":"2018","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"24","key":"10.1016\/j.jcyt.2020.01.015_bib0042","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1158\/1078-0432.CCR-18-0426","article-title":"A Phase I\/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia","volume":"24","author":"Enblad","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.jcyt.2020.01.015_bib0043","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jcyt.2020.01.015_bib0044","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bjh.15195","article-title":"Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB","volume":"181","author":"Li","year":"2018","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.jcyt.2020.01.015_bib0045","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.jcyt.2020.01.015_bib0046","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1017\/S147895151600095X","article-title":"Chimeric antigen receptor T-cell neuropsychiatric toxicity in acute lymphoblastic leukemia","volume":"15","author":"Prudent","year":"2017","journal-title":"Palliat Support Care"},{"issue":"8","key":"10.1016\/j.jcyt.2020.01.015_bib0047","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.jcyt.2020.01.015_bib0048","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.tmrv.2019.01.005","article-title":"Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis","volume":"33","author":"Grigor","year":"2019","journal-title":"Transfus Med Rev"},{"issue":"8","key":"10.1016\/j.jcyt.2020.01.015_bib0049","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00277-018-3368-8","article-title":"The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review","volume":"97","author":"Jin","year":"2018","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.jcyt.2020.01.015_bib0050","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"17","key":"10.1016\/j.jcyt.2020.01.015_bib0051","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.2174\/0929867324666170801101842","article-title":"Adoptive immunotherapy for B-cell malignancies using CD19-targeted chimeric antigen receptor T-cells: A systematic review of efficacy and safety","volume":"26","author":"Hao","year":"2017","journal-title":"Curr Med Chem"},{"issue":"22","key":"10.1016\/j.jcyt.2020.01.015_bib0052","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood.V128.22.587.587","article-title":"Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute Lymphoblastic Leukemia - Three-Year Follow-up of a Multicenter Phase I\/II Study","volume":"128","author":"Lung-Ji","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2020.01.015_bib0053","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/TCRM.S150524","article-title":"Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy","volume":"15","author":"Riegler","year":"2019","journal-title":"Ther Clin Risk Manag"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324920300359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324920300359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:40:55Z","timestamp":1761442855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324920300359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S1465324920300359"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2020.01.015","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor\u2013T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2020.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Society for Cell and Gene Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}